Results 41 to 50 of about 8,934 (195)

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol

BMC Musculoskeletal Disorders, 2019
Background A tenosynovial giant cell tumor (TGCT) is a locally aggressive benign neoplasm arising from intra- or extra-articular tissue. Diffuse TGCT (D-TGCT) most commonly develops in the knee, followed by the hip, ankle, elbow, and shoulder.
Akihiko Takeuchi, Akihiro Nomura, Norio Yamamoto, Katsuhiro Hayashi, Kentaro Igarashi, Susumu Tandai, Akira Kawai, Akihiko Matsumine, Shinji Miwa, Yoshihiro Nishida, Tomoki Nakamura, Ryu Terauchi, Manabu Hoshi, Toshiyuki Kunisada, Makoto Endo, Kenichi Yoshimura, Toshinori Murayama, Hiroyuki Tsuchiya   +17 more
doaj   +1 more source

Tenosynovial giant cell tumours: experience at an Australian tertiary referral centre for musculoskeletal tumours with minimum two-year follow-up

Bone & Joint Open, 2023
Aims: Tenosynovial giant cell tumour (TGCT) is a rare benign tumour of the musculoskeletal system. Surgical management is fraught with challenges due to high recurrence rates. The aim of this study was to describe surgical treatment and evaluate surgical
Raymond G. Kim, Anthony W. Maher, Sascha Karunaratne, Paul D. Stalley, Richard A. Boyle   +4 more
doaj   +1 more source

Testicular histopathology and its association with germ cell numbers, serum concentrations of reproductive hormones, and semen quality

Andrology, EarlyView.
Abstract Background It is well‐established that spermatogenesis, semen quality, and reproductive hormones are interlinked. It is, however, less well‐described how various specific testicular histopathologies are linked to reproductive hormones and semen quality.
Gülizar Saritas, Nina Mørup, Trine H. Johannsen, Anders Juul, Lise Aksglaede, Sofia B. Winge, Kristian Almstrup   +6 more
wiley   +1 more source

BRD9 inhibition as potential treatment option for testicular germ cell tumors

Andrology, EarlyView.
Abstract Background Testicular germ cell tumors (TGCT) are the predominant tumor in younger males. Usually, 5‐year survival rates are quite high, but 15–20% of patients with metastatic non‐seminomas are resistant to standard cisplatin‐based therapy.
Aylin Hansen, Christine Sanders, Florian Fronhoffs, Kai Funke, Glen Kristiansen, Hubert Schorle   +5 more
wiley   +1 more source

Mapping 12p amplicons in TGCT genomes.

, 2019
Copy number aberrations on chromosome 12p in three distinct TGCT aneuploid populations. The 12p amplicons included the whole 12p arm (3/5 cases) in a 2.8N population detected in case #3 and two distinct amplicons in the 2.7N and the 3.2N populations ...
Melissa Stanton (3493625), Lance Pagliaro (6458957), James Slack (6458954), Michael T. Barrett (117067), Paul Andrews (3505823), Elzbieta Lenkiewicz (6458951), Smriti Malasi (5505893), Alan H. Bryce (523011)   +7 more
core   +1 more source

Sperm Telomere Interactions Are Impaired in Testicular Cancer Before and After Adjuvant Therapy

Andrology, EarlyView.
ABSTRACT Background No study has yet explored telomere length or interaction in sperm nuclei of testicular cancer (TC) patients exposed to chemotherapy or radiotherapy. However, sperm telomere dynamics have emerged as a potential marker in male infertility.
Benoit Berby, Sylvianne Hennebicq, Jacqueline Saias, Florence Brugnon, Isabelle Berthaut, Myriam Daudin, Louis Bujan, Ludovic Dumont, Christine Rondanino, Aurélie Feraille, Nathalie Rives   +10 more
wiley   +1 more source

Cell lineage of metastatic TGCT.

, 2019
A) Genomic aberrations within primary and refractory metastatic TGCT in case #1 include; i) shared XRCC2R188H and RITA1T220K mutations in an inferred malignant progenitor; ii) CNVs, 12p13.31-p11.21 amplicon, gain of 7p13.1-ptel, and loss of chromosome 9,
Melissa Stanton (3493625), Lance Pagliaro (6458957), James Slack (6458954), Michael T. Barrett (117067), Paul Andrews (3505823), Elzbieta Lenkiewicz (6458951), Smriti Malasi (5505893), Alan H. Bryce (523011)   +7 more
core   +1 more source

Clinical significance of immunocyte- and ferroptosis-related markers for the prognosis of patients with tenosynovial giant cell tumor: A cross-sectional study

Cancer Treatment and Research Communications
Background: Tenosynovial giant cell tumor (TGCT) comprises localized (L-TGCT) and diffuse (D-TGCT) subtypes, but how ferroptosis regulators, tumor-associated immune-cell markers and proliferation indices jointly relate to subtype and recurrence is poorly
Zhi-qiang Song, Yesitai Saierhali, Chen‑xi Li, Meng Wang, Bo Shao, Li Wang, Zhong‑cheng Gong   +6 more
doaj   +1 more source

Risk of osteoporosis in testicular germ cell tumour survivors: A systematic review of the literature

BJUI Compass, 2023
Context Testicular germ cell tumour (TGCT) survivors are potentially at risk of developing osteoporosis, because of increased risk for disturbed bone remodelling associated with hypogonadism and anti‐cancer treatment.
Josephina P. M. Vrouwe, Pauline M. L. Hennus, Neveen A. T. Hamdy, Susanne Osanto, Peter‐Paul M. Willemse   +4 more
doaj   +1 more source